Table 3 General characteristics of stages IIIB and IV lung adenocarcinoma patients under TKI treatment with and without lung cancer salvage surgery by propensity score matching with control of age, gender, clinical stage, and smoking habit
|  | TKI with OP (n = 16) | TKI without OP (n = 16) | P-value |
|---|---|---|---|
Age | 62.94 + 11.58 | 63.75 + 10.56 | 0.837 |
Gender | |||
 Male | 6 (37.5%) | 7 (43.75%) | 0.729 |
 Female | 10 (62.5%) | 9 (56.25%) |  |
Smoking | |||
 Yes | 5 (31.25%) | 9 (56.25%) | 0.164 |
 None | 11 (68.75%) | 7 (43.75%) |  |
Grade of differentiation | |||
 Moderate | 12 (75%) | 9 (56.25%) | 0.279 |
 Poor | 4 (25%) | 7 (43.75%) |  |
Operation | |||
 Lobectomy | 6 (37.5%) |  |  |
 Wedge or segmentectomy | 10 (62.5%) |  |  |
Performance status | |||
 0 | 9 (56.25%) | 8 (50%) | 0.723 |
 1 | 7 (43.75%) | 8 (50%) |  |
Clinical stage | |||
 IIIB | 1 (6.25%) | 0 | 0.325 |
 IVA m1a | 6 (37.5%) | 3 (18.75%) | 0.252 |
 IVA m1b | 2 (12.5%) | 6 (37.5%) | 0.109 |
 IVB | 7 (43.75%) | 7 (43.75%) | 1 |
Metastases | |||
 Lung or pleura | 15 (93.75%) | 11 (68.75%) | 0.074 |
 Brain | 5 (31.25%) | 3 (18.75%) | 0.431 |
 Adrenal gland | 0 | 5 (31.25%) | 0.014 |
 Bone | 6 (37.5%) | 13 (81.25%) | 0.011 |
 Liver | 6 (37.5%) | 6 (37.5%) | 1 |
EGFR mutation | |||
 L858R | 6 (37.5%) | 6 (37.5%) | 1 |
 Exon 19 deletion | 10 (62.5%) | 10 (62.5%) |  |
TKI usage duration (month) | 40.4 ± 20.7 | 14.96 ± 13.13 | < 0.001 |
Survival | |||
 Yes | 10 (62.5%) | 4 (25%) | 0.033 |
 None | 6 (37.5%) | 12 (75%) |  |
Overall survival | 42.32 ± 19.33 | 17.05 ± 13.49 | < 0.001 |